title: The role of activated adenosine receptors in degranulation of human LAD2 mast cells.
abstract: Mast cell degranulation triggers hypersensitivity reactions at the body-environment interface. Adenosine modulates degranulation, but enhancement and inhibition have both been reported. Which of four adenosine receptors (ARs) mediate modulation, and how, remains uncertain. Also uncertain is whether adenosine reaches mast cell ARs by autocrine ATP release and ecto-enzymatic conversion. Uncertainties partly reflect species and cell heterogeneity, circumvented here by focusing on homogeneous human LAD2 cells. Quantitative PCR detected expression of A2A, A2B, and A3, but not A1, ARs. Nonselective activation of ARs with increasing NECA monotonically enhanced immunologically or C3a-stimulated degranulation. NECA alone stimulated degranulation slightly. Selective AR antagonists did not affect C3a-stimulated degranulation. NECA's enhancement of C3a-triggered degranulation was partially inhibited by separate application of each selective antagonist, and abolished by simultaneous addition of antagonists to the three ARs. Only the A2A antagonist separately inhibited NECA's enhancement of immunologically stimulated degranulation, which was abolished by simultaneous addition of the three selective antagonists. Immunological or C3a activation did not stimulate ATP release. NECA also enhanced immunologically triggered degranulation of mouse bone marrow derived mast cells (BMMCs), which was partially reduced only by simultaneous addition of the three antagonists or by the nonselective antagonist CGS15943. BMMCs also expressed A2A, A2B, and A3 ARs. but not A1AR detectably. We conclude that (a) A1AR is unnecessary for LAD2 degranulation or AR enhancement; (b) A2A, A2B, and A3 ARs all contribute to pharmacologic AR enhancement of LAD2 and BMMC degranulation; and (c) LAD2 cells depend on microenvironmental adenosine to trigger AR modulation.
authors.affiliation: Department of Physiology, University of Pennsylvania School of Medicine, A303 Richards Building, Philadelphia, PA, 19104-6085, USA.
authors.forename: Chi Ting
authors.initials: CT
authors.lastname: Leung
authors.forename: Ang
authors.initials: A
authors.lastname: Li
authors.forename: Juni
authors.initials: J
authors.lastname: Banerjee
authors.forename: Zhan-Guo
authors.initials: ZG
authors.lastname: Gao
authors.forename: Taku
authors.initials: T
authors.lastname: Kambayashi
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Jacobson
authors.forename: Mortimer M
authors.initials: MM
authors.lastname: Civan
mesh_terms: D000818:Animals; D002460:Cell Line; D006801:Humans; D008407:Mast Cells / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D058915:Purinergic P1 Receptor Antagonists / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology; D018047:Receptors, Purinergic P1 / Q000378:metabolism*; D014230:Triazoles / Q000494:pharmacology
chemical_list: D058915:Purinergic P1 Receptor Antagonists; D011799:Quinazolines; D018047:Receptors, Purinergic P1; D014230:Triazoles; C052410:9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine